Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Recruiting

A Study of AZD4512 Alone or With Other Cancer Drugs for People With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

Fast replyInvestigational
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

What is this trial about?

A plain-language summary of the goals, design and what participants do

This study is looking at a type of cancer called Non-Hodgkin lymphoma, which is a disease that affects certain white blood cells in the body's immune system, specifically B-cells. The study focuses on patients whose cancer has come back after treatment or has not responded to previous treatments. The treatment being tested is AZD4512, which is an antibody drug conjugate, meaning it is a medicine that combines an antibody with a cancer-fighting drug to target cancer cells more directly. The study will look at AZD4512 when used alone or together with other cancer medicines.

The purpose of this study is to learn how safe AZD4512 is and how well the body can tolerate it, and to find the right dose that can be used for treatment. The study will also look at how the medicine moves through the body, how it affects the disease, and whether the body's immune system reacts to it. During the study, participants will receive the medicine through an infusion into a vein. Doctors will monitor participants closely by checking vital signs, doing blood tests, and using imaging scans such as PET scans and CT or MRI scans to see how the disease responds to treatment. These scans are special types of medical imaging that help doctors see inside the body and measure the size of lymphoma areas.

The study will track various aspects including any side effects that occur, how long any positive responses to treatment last, and how long participants live. Doctors will also measure the levels of the medicine in the blood and check if the body develops any immune responses to it. The response to treatment will be assessed using a specific classification system for lymphoma that looks at whether the cancer shrinks, stays the same, or grows during treatment. This is a phase one and phase two study, which means it is an early stage of testing to gather important information about the new treatment.

The research process

The trial runs in 7 steps – from screening to follow-up. Each step says what happens and what the team monitors.

  1. Step 1

    Initial treatment period

    You will receive AZD4512 as a single treatment or in combination with other cancer medications.

    The medication will be administered through intravenous infusion, which means it will be delivered directly into your vein over a period of time.

    The treatment will be given in cycles. The exact dose, frequency, and duration will be determined by the study doctor based on your response to the medication.

  2. Step 2

    Safety monitoring period

    During the initial treatment phase, you will be closely monitored for any side effects or adverse reactions to determine the appropriate dose of the medication.

    Your vital signs, such as blood pressure, heart rate, and temperature, will be measured regularly.

    Blood samples will be taken to check your organ function and blood cell counts to ensure your body is tolerating the treatment.

    Any side effects you experience will be recorded and assessed for their severity and duration.

  3. Step 3

    Disease assessment

    You will undergo imaging scans to measure the size of your lymphoma. This may include PET scans (a type of imaging that shows metabolic activity in your body), CT scans (detailed X-ray images), or MRI scans (magnetic imaging).

    These scans will help determine how your lymphoma is responding to the treatment.

    The response will be evaluated according to established classification systems for lymphoma.

  4. Step 4

    Blood sample collection for medication levels

    Blood samples will be collected at specific times to measure the levels of AZD4512 and its components in your bloodstream.

    These measurements help understand how your body processes the medication, including how quickly it is absorbed, distributed, and eliminated.

    The timing of these blood draws will be scheduled around your treatment infusions.

  5. Step 5

    Immune response testing

    Blood samples will be taken to check if your body develops an immune response to the medication.

    This involves testing for anti-drug antibodies, which are proteins your immune system might produce in response to the treatment.

    This information helps assess how your immune system is reacting to the medication over time.

  6. Step 6

    Continued treatment cycles

    If you tolerate the treatment well and your lymphoma responds positively, you will continue receiving AZD4512 in repeated cycles.

    The treatment will continue as long as it is beneficial for you and you do not experience unacceptable side effects.

    Regular monitoring of your health status, blood tests, and imaging scans will continue throughout your participation.

  7. Step 7

    Long-term follow-up

    After completing the treatment phase, you will be followed for an extended period to monitor your overall survival and long-term health outcomes.

    This follow-up will continue to track the duration of your response to treatment and whether the lymphoma returns.

    The total duration of your participation in the study may extend until 2028, depending on when you join and how you respond to treatment.

Who can join the trial?

8 criteria

  • You must be 18 years of age or older
  • You must be able to understand and follow the study requirements and sign an informed consent, which is a document explaining the study that you agree to by signing
  • You must have measurable disease, meaning tumors that can be seen and measured on scans. For lymphomas that show up on FDG-PET scans (a special type of imaging test that uses a radioactive sugar to detect cancer), you need at least one tumor in a lymph node larger than 1.5 centimeters in its longest dimension, or at least one tumor outside lymph nodes larger than 1 centimeter. For lymphomas that do not show up well on FDG-PET scans, the same size requirements apply when measured on CT or MRI scans (other types of imaging tests)
  • Your ECOG Performance Status must be 2 or lower. This is a score from 0 to 5 that measures how well you can perform daily activities, where 0 means you are fully active and 2 means you can care for yourself but cannot work
  • Your life expectancy must be at least 12 weeks, meaning doctors expect you to live for at least 3 months
  • You must have adequate organ and bone marrow function, meaning your organs such as liver, kidneys, and bone marrow must be working well enough to handle the study treatment
  • You or your partner must use appropriate contraception (birth control methods) as required by local regulations during the study to prevent pregnancy
  • You must be able to attend all required study visits, follow the treatment plan, and complete all study procedures

Who cannot join the trial?

18 criteria

  • You have primary central nervous system lymphoma, which means lymphoma that started in your brain or spinal cord
  • You have a history of another type of cancer within the last 2 years, except for certain skin cancers or cancers that have been completely removed
  • You have active infection requiring treatment with antibiotics or antiviral medicines
  • You have known infection with HIV, which is a virus that affects the immune system
  • You have active infection with hepatitis B or C, which are viruses that affect the liver
  • You have had a stem cell transplant within the last 100 days, which is a treatment where blood-forming cells are replaced
  • You have graft versus host disease requiring treatment, which is a condition where transplanted cells attack your body
  • You have significant heart problems, including recent heart attack, unstable chest pain, or severe heart rhythm problems
  • You have uncontrolled high blood pressure despite taking medicines to lower it
  • You have severe lung disease requiring oxygen therapy
  • You have severe liver problems that affect how your liver works
  • You have severe kidney problems requiring dialysis, which is a treatment to clean your blood when kidneys don't work properly
  • You have a history of bleeding problems or stroke
  • You are pregnant or breastfeeding
  • You have received certain cancer treatments within a specific time period before joining the study
  • You have received a live vaccine within 30 days before starting the study treatment
  • You have a known allergy to the study medicine or its ingredients
  • You are taking certain medicines that cannot be stopped or changed during the study
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Verified sites

All sites with verified contact details – recruitment status may not be available; ask directly

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

Recruiting
Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

AZD4512 is an experimental medication being tested in this study. It is being evaluated as a treatment for people with a type of cancer called B-cell non-Hodgkin lymphoma that has come back after previous treatment or has not responded to treatment. This medication may be given alone or together with other cancer medicines to see how safe it is and how well it works against this type of cancer.

What is already known about the treatment

AZD4512 – AZD4512 is an experimental anticancer medication currently being studied in clinical trials for the treatment of relapsed or refractory B-cell Non-Hodgkin lymphoma, which is a type of cancer affecting the immune system's white blood cells. The medication is being evaluated as a monotherapy (used alone) or in combination with other anticancer agents to determine its safety, proper dosing, and effectiveness in patients whose disease has returned or has not responded to previous treatments. As an investigational drug, it is not yet approved for general medical use and is only available through clinical trial participation. The study aims to understand how the medication works in the body, its side effects, and the best dose to use for treating this specific type of blood cancer.

Investigated diseases

Non-Hodgkin Lymphoma – Non-Hodgkin lymphoma is a type of cancer that develops in the lymphatic system, which is part of the body's immune system. It occurs when white blood cells called lymphocytes grow abnormally and uncontrollably, forming tumors in lymph nodes or other parts of the body. The disease can start in different types of lymphocytes, most commonly B-cells or T-cells. As the condition progresses, abnormal lymphocytes can accumulate in lymph nodes, causing them to swell, and may spread to other organs such as the spleen, liver, or bone marrow. The disease can develop slowly over many years or grow rapidly, depending on the specific type. Non-Hodgkin lymphoma encompasses many different subtypes, each with distinct characteristics and patterns of growth.
Trial detailsLast updated 2 Oct 2026
Age18+ yearsPhasePhase I/IITrial ID2025-522371-29-00Protocol codeD9890C00001Estimated enrolment151 patientsSponsorAstraZeneca AB

sourced from the EU Clinical Trials Register and site verification

Want to learn more about this trial or check if you can participate?

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

ClinicalTrials.eu

Every clinical trial in Europe, in plain language.

Explore the full ecosystem of clinical research in Europe.

Search trials

Legal notice · Published by CTIN POLAND sp. z o.o., ul. rtm. Witolda Pileckiego 67/109, 02-781 Warsaw, Poland · KRS 0001111334 · REGON 528919042 · NIP 9512598637

© 2026 Clinical Trials EU – European Clinical Trials Information Network

GDPR compliance, ISO 9001 and ISO 27001 certified (LL-C Certification)

On this site, “treatment” means an investigational medicine being studied in a clinical trial. Its safety and efficacy for the use being studied have not yet been confirmed, some participants may receive a placebo or a comparator medicine, and taking part does not guarantee any health benefit. The decision to take part is made by the doctor at the research site. This site is for information only and does not replace medical advice.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic sites, national regulators and commercial sponsors. On this site, “treatment” and “therapy” mean a medicine being tested in a clinical trial. Its safety and effectiveness in the use being studied are not yet confirmed, some participants may receive a placebo or a comparator, and taking part does not guarantee a health benefit. The doctor at the research site decides who can take part. This site provides information, not medical advice. Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).